New Remdesivir Trial Tests Drug in Combination with Baricitinib

New patients are currently being enrolled in the University of Illinois at Chicago’s second clinical trial to study the drug remdesivir as a treatment for COVID-19.

 According to the college, the international randomized, placebo-controlled clinical trial will study the antiviral drug in combination with an anti-inflammatory drug used to treat rheumatoid arthritis called baricitinib.

This trial follows the National Institute of Allergy and Infectious Disease’s Adaptive COVID-19 Treatment Trial in which results showed that patients who were treated with remdesivir recovered faster than those who were in the control group and received a placebo.

Read the story at: today.uic.edu/new-remdesivir-trial-at-uic-tests-drug-in-combination-with-baricitinib